Detection and clinical relevance of micrometastatic cancer cells

Current Opinion in Oncology

Volumn 12, Issue 1, 2000, Pages 95-101

  Pantel, Klaus ^a   Von Knebel Doeberitz, Magnusvon ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID;

ASSAY; BONE MARROW METASTASIS; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER STAGING; CARCINOMA CELL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; EARLY DIAGNOSIS; EPITHELIUM; HUMAN; IMMUNOCYTOCHEMISTRY; LYMPH NODE METASTASIS; METASTASIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

BIOLOGICAL ASSAY; CARCINOMA; DIAGNOSIS, DIFFERENTIAL; DNA, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034518343     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200001000-00016     Document Type: Review

References (90)

1. Detection and clinical importance of micrometastatic disease
2. Cytokeratins in the histological diagnosis of malignant tumors
3. Cytokeratin expression patterns in normal and malignant urothelium: A review of the biological and diagnostic implications
4. Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone marrow
5. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
6. Micrometastatic cancer cells in bone marrow: In vitro detection with anti-cytokeratin and in vivo labeling with anti-17-1A monoclonal antibodies
7. Low specificity of cytokeratin 19 reverse transcriptase-polymerase chain reaction analyses for detection of hematogenous lung cancer dissemination
8. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
9. Meta-analyses of studies on bone marrow micrometastases: An independent prognostic impact remains to be substantiated
10. Outcome of primary-breast-cancer patients with micrometastases: A long-term follow-up study
11. Standardization of the immunocytochemical detection of cancer cells in bone marrow and blood
12. Prognostic significance of bone marrow micrometastases in patients with gastric cancer
13. Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: A reference to early systemic disease in solid cancer
14. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer
15. Application of immunomagnetic beads in combination with RT-PCR for the detection of circulating prostate cancer cells
16. Detection of prostatic specific membrane antigen messenger RNA using immunobead reverse transcriptase polymerase chain reaction
17. Immunocytochemical detection of isolated epithelial cells in bone marrow: Non-specific staining and contribution by plasma cells directly reactive to alkaline phosphatase
18. Increased sensitivity for detection of micrometastases in bone-marrow/peripheral-blood stem-cell products from breast-cancer patients by negative immunomagnetic separation
19. Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood
20. Immunomagnetic enrichment of disseminated epithelial tumor cells from peripheral blood by MACS
21. Nucleic acid based techniques for the detection of rare cancer cells in clinical samples
22. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence
23. Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method
24. Genetic diagnosis of lymph-node metastasis in colorectal cancer
25. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
26. Molecular detection of primary bladder cancer by microsatellite analysis
27. Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes
28. Microsatellite analysis of plasma DNA from patients with clear cell renal carcinoma
29. Microsatellite alterations in serum DNA of head and neck cancer patients
30. Detection of chromosome 3p alterations in serum DNA of non-small-cell lung cancer patients
31. Microsatellite alterations in plasma DNA of small cell lung cancer patients
32. Molecular detection of genetic alterations in the serum of colorectal cancer patients
33. Plasma DNA microsatellites as tumor-specific markers and indicators of tumor progression in melanoma patients
34. Detecting tumor-related alterations in plasma or serum DNA of patients diagnosed with breast cancer
35. Molecular detection of neoplastic cells in lymph nodes of metastatic colorectal cancer patients predicts recurrence
36. Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck
37. Nucleic acid-based methods for the detection of cancer
38. Utilization of polymerase chain reaction technology in the detection of solid tumors
39. Molecular detection of micrometastases and circulating tumor cells in solid tumors
40. Detection of SYT-SSX1/2 fusion transcripts by reverse transcriptase- polymerase chain reaction (RT-PCR) is a valuable diagnostic tool in synovial sarcoma
41. Analysis of FUS-CHOP fusion transcripts in different types of soft tissue liposarcoma and their diagnostic implications
42. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of micrometastasis in cervical cancer?
43. Molecular detection of micrometastases and circulating tumor cells in solid tumors
44. Identification of superior markers for polymerase chain reaction detection of breast cancer metastases in sentinel lymph nodes
45. Detection of metastases in sentinel lymph nodes of breast cancer patients by multiple-marker RT-PCR
46. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow
47. Limitations of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients
48. Identification of a novel cytokeratin 19 pseudogene that may interfere with reverse transcriptase-polymerase chain reaction assays used to detect micrometastatic tumor cells
49. Analysis of potential markers for detection of submicroscopic lymph node metastases in breast cancer
50. Specificity of reverse transcriptase polymerase chain reaction assays designed for the detection of circulating cancer cells is influenced by cytokines in vivo and in vitro
51. Comparative analysis of bone marrow and venous blood isolates from gastrointestinal cancer patients for the detection of disseminated tumor cells using reverse transcription PCR
52. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma
53. Association between molecular detection of GAGE and survival in patients with malignant melanoma: A retrospective cohort study
54. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma
55. Prognostic significance of the detection of circulating malignant cells by reverse transcriptase-polymerase chain reaction in long-term clinically disease-free melanoma patients
56. Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: Association with clinical stage and prognosis
57. New prognostic factors in melanoma: mRNA tumour markers
58. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: Clinical implications
59. Clinical and molecular followup after radical retropubic prostatectomy
60. Molecular staging of prostate cancer: Dream or reality?
61. Quality management and influential factors for the detection of single metastatic cancer cells by reverse transcriptase polymerase chain reaction
62. Detection of disseminated tumor cells in peripheral blood of colorectal cancer patients
63. Dissemination of tumor cells in patients undergoing surgery for colorectal cancer
64. Disseminated tumor cells in lymph nodes as a determinant for survival in surgically resected non-small-cell lung cancer
65. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer
66. Detection of disseminated colorectal cancer cells in lymph nodes, blood and bone marrow
67. Micrometastases and survival in stage II colorectal cancer
68. Comparative genomic hybridization, loss of heterozygosity, and DNA sequence analysis of single cells
69. Multiple mutation analyses in single tumor cells with improved whole genome amplification
70. p53 gene mutations are not required for early dissemination of cancer cells
71. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: Establishment of working models for human micrometastases
72. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
73. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients
74. Chromosome 17-mediated dormancy of AT6.1 prostate cancer micrometastases
75. Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: Results of a 3-year median follow-up
76. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases
77. Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status
78. Cytokeratin-positive bone marrow micrometastasis and survival of breast cancer patients with stage I-III disease
79. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal cancer patients
80. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: Methodological aspects of detection and prognostic significance
81. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer
82. Micrometastases in bone marrow: Prognostic indicators for pancreatic cancer
83. Disseminated epithelial tumor cells in bone marrow of patients with esophageal cancer: Detection and prognostic significance
84. Detection of occult bone marrow micrometastases in patients with operable lung carcinoma
85. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases
86. Micrometastatic tumor cells in the bone marrow of patients with non-small cell lung cancer
87. Epithelial tumor cells in bone marrow of patients with colorectal cancer: Immunocythochemical detection, phenotypic characterization, and prognostic significance
88. Frequent down-regulation of major histocompatibility class I antigen expression on individual micrometastic carcinoma cells
89. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells
90. Prognostic significance of micrometastatic bone marrow involvement